The Efficacy and Safety of IBI363 in Solid Tumors.
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The study is a prospective multi-cohort clinical study. The study is divided into two phases,
Phase Ia and Phase Ib. In Phase Ia, a dose escalation portion was conducted using a 3+3
dose-escalation design, with a preference for enrolling subjects with advanced non-small cell
lung cancer and melanoma. Phase Ib represents the cohort expansion phase, comprising seven
cohorts.